News

APG-115 has been designed by Ascentage Pharma as an orally administered, selective, small-molecule inhibitor of the MDM2-p53 PPI. KEYTRUDA, on the other hand, is an anti-PD-1 therapy, which

As part of the conditional marketing authorisation, Veklury will be used to treat Covid-19 disease in adults and adolescents, aged 12 years and older and weighing at least

Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6,

As part of the agreement, KKR will acquire its stake from the founding Mody family at a purchase price of INR 745 per share and make an open

Rukobia is a novel attachment inhibitor, which is designed to treat HIV-1 infection, is specified for use in combination with other antiretroviral (ARV) therapies in heavily treatment-experienced (HTE)

Patients with TNBC, an aggressive subtype of breast cancer, have limited treatment options beyond standard chemotherapy. High TROP2 expression has been reported in up to 80 percent of

The BNT162 program is evaluating at least four experimental vaccines, each of which represents a unique combination of mRNA format and target antigen. The manuscript describing the preliminary

As a result of the approval, Janssen is currently collaborating with the World Health Organisation (WHO) on vaccine pre-qualification to advance the registration of its preventive Ebola vaccine

CONTACT-02 is part of a clinical trial collaboration between Exelixis and Roche that includes two additional phase 3 pivotal trials – CONTACT-01 in patients with metastatic non-small cell